Opticin a Treatment for Cancer and Angiogenesis
BACKGROUND Opticin is a protein present in the eye (in the vitreous humour) and was discovered at University of Manchester by Dr Paul Bishop. Uniquely Opticin has been found to exhibit both cytotoxic AND anti-angiogenic (blood vessel formation) effects on a range of cell lines from different cancers. Currently there is considerable interest in developing drugs derived from natural endogenous molecules with cytotoxic/anti-proliferative effects for treating cancer, as these are less likely to have severe side effects as compared to conventional pharmaceutical agents. THE TECHNOLOGY A recombinant endogenous molecule has been isolated with both anti-angiogenic and anti-proliferative activity. In vitro and in vivo tests show significant inhibition of cell proliferation and new blood vessel formation. Cell lines are being developed for biomanufacturing. KEY BENEFITS
• Retards tumour growth
• Active in a range of tumour cell lines
• Prevents vessel infiltration APPLICATIONS Treatment of:
• cancer (angiogenesis and tumour growth)with activity in breast, lung, glioma, colon, bladder, pancreatic and bone cell lines
• diabetic retinopathy (angiogenesis)
• Age related macular degeneration
• rheumatoid arthritis (angiogenesis in the pannus).
• cardiology/vascular medicine (anti-coagulation)
PATENT STATUS Patent at UK priority and a second at PCT stage. OPPORTUNITY Of interest to Biotech and Pharma companies and agencies with a view to collaborative research and development in one or more indications as a candidate drug. Option or licence agreement possible.
Type of Offer:
« More Biotech Patents« More Pharmaceutical Patents